Arkolith/Insider Trading/PSTX/Form 4

Gergen Mark J

President and CEO, DirectorPoseida Therapeutics, Inc. (PSTX) · full profile →Form 4 · filed Jan 8, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 8, 2025Tender(U)637K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 8, 2025Disposed to issuer(D)241K—$00
Jan 8, 2025Disposed to issuer(D)173K—$00
Jan 8, 2025Disposed to issuer(D)48K—$00
Jan 8, 2025Disposed to issuer(D)519K—$00
Jan 8, 2025Disposed to issuer(D)364K—$00
Jan 8, 2025Disposed to issuer(D)75K—$00
Jan 8, 2025Disposed to issuer(D)342K—$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-001081) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML